About Ourotech
A patient that is diagnosed with cancer today will have a genetic screen on their tumor sample to determine their subtype of cancer. Based on the cancer subtype, they are given a first line of treatment. If that doesn't work, they are given a second line of treatment. If that doesn't work, they are given a third line of treatment. Why experiment with a patient's body; wasting time and risking their life?
Drugs fail because of drug resistance. Ourotech measures drug resistance on a patient's tumor sample outside of their body so we can determine the best cancer treatment the first time. Ourotech has created a hydrogel that can culture tumors outside of the human body and mimic the drug resistance of tumors inside the human body. We use IC50, the industry standard for measuring drug resistance, so we can determine the best treatment for a patient and eliminate the trial and error process.
- Founding: 2015
- Focus : Manufacturer
- Employees: 1-10
- Industry : Diagnostics
Product portfolio of Ourotech
Here you will find Ourotech
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
